FDA investigating possible increased risk of death with lymphoma medicine Ukoniq (umbralisib)
FDA investigating possible increased risk of death with lymphoma medicine Ukoniq (umbralisib)
What to do next
Read the issuing agency's notice carefully, compare the product identifiers, and follow the official remedy instructions. RecallDefense helps you keep watch, but the source agency's notice is the authority for action.
Source attribution: FDA. Published Feb 3, 2022.
